Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
Descriptor ID |
D047428
|
MeSH Number(s) |
D27.505.519.389.755
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 | 1996 | 0 | 2 | 2 | 1997 | 0 | 1 | 1 | 1998 | 0 | 1 | 1 | 1999 | 0 | 1 | 1 | 2002 | 0 | 1 | 1 | 2004 | 1 | 3 | 4 | 2005 | 7 | 3 | 10 | 2006 | 5 | 8 | 13 | 2007 | 6 | 5 | 11 | 2008 | 5 | 6 | 11 | 2009 | 11 | 4 | 15 | 2010 | 17 | 14 | 31 | 2011 | 11 | 10 | 21 | 2012 | 22 | 8 | 30 | 2013 | 23 | 9 | 32 | 2014 | 16 | 7 | 23 | 2015 | 14 | 16 | 30 | 2016 | 18 | 11 | 29 | 2017 | 9 | 12 | 21 | 2018 | 12 | 10 | 22 | 2019 | 13 | 9 | 22 | 2020 | 5 | 12 | 17 | 2021 | 13 | 9 | 22 | 2022 | 0 | 5 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Gambacorti-Passerini C, Nicolini FE, Larson RA, Aroldi A, Fontana D, Piazza R, le Coutre P, Antolini L, Assouline S. Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. Am J Hematol. 2022 08; 97(8):E296-E298.
-
Johnson M, Garassino MC, Mok T, Mitsudomi T. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer. 2022 Aug; 170:41-51.
-
Ascierto PA, Warner AB, Blank C, Caracò C, Demaria S, Gershenwald JE, Khushalani NI, Long GV, Luke JJ, Mehnert JM, Robert C, Rutkowski P, Tawbi HA, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. J Transl Med. 2022 05 10; 20(1):200.
-
Strohbehn GW, Ratain MJ. Lorlatinib Exposed: A Far From Optimal Dose. Clin Pharmacol Ther. 2022 06; 111(6):1195-1196.
-
Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE. Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. J Natl Cancer Inst. 2022 01 11; 114(1):160-164.
-
Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Hernando Fernández de Aránguiz B, Haddad TC, Perelló A, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022 01 20; 40(3):282-293.
-
Wu J, Galvan KJ, Bogard RD, Peterson CE, Shergill A, Crowe DL. DNA Double-strand Break Signaling Is a Therapeutic Target in Head and Neck Cancer. Anticancer Res. 2021 Nov; 41(11):5393-5403.
-
Kinoshita S, Colby KA, Kruse FE. A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy. Cornea. 2021 Oct 01; 40(10):1225-1228.
-
Clarke WA, Chatelut E, Fotoohi AK, Larson RA, Martin JH, Mathijssen RHJ, Salamone SJ. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy. Eur J Cancer. 2021 11; 157:428-440.
-
Hwang J, Singh N, Braniecki M, Gok Yavuz B, Tsoukas MM, Quigley JG. Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis. Br J Haematol. 2021 11; 195(3):e138-e141.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|